Quick Dispatch:
Your surpass-cvot tirzepatide SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass-cvot tirzepatide SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I ships.
Need Help?
Questions about surpass-cvot tirzepatide SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass-cvot tirzepatide SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I in your area.
SURPASS-CVOT — Leicester Diabetes Centre
28.15
Overview of key tirzepatide clinical trials and their cardiovascular
25.73
Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and
20.34
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT
28.94
Diabetes Distilled: SURPASS-CVOT – Tirzepatide demonstrates cardiovascular benefit in secondary prevention
23.75
ACC 26: SURPASS-CVOT
22.31
SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I
22.03
